thought manag meet
execut rais pt
quick read monster perform februari
lukewarm start tax season guidanc
color fundament focu call
rockstar main act expect reiter outperform
updat ampl bridg clinic data gap
report look pipelin newsflow sci-b-vac
head toward us/eu review approv
review build commerci voclosporin
review slowli build
analyst certif import disclosur see
reduc group estim coronaviru drag
presid kurt siever nomin ceo
report jan earn wednesday see result line w/consensu sales/ep est
importantli surprisingli see modest downsid bia apr sales/ep reflect
group-wid coronaviru headwind reduc top line reduct line w/peer increas
sale est leav ep unchang coronaviru situat remain fluid make depth/dur impact
supply/demand difficult project see near-term drag transitori order push forward vs cancel
alway investor focu lora commentari sale expect vs dc/pon
benefit recoveri hyperscal spend risk/reward appear favor view possibl
lora fail ramp de facto iot lpwan standard maintain outperform
thought manag meet
recently-hir cfo tom ondrof emphas achiev msd revenu growth margin profil much
closer previou employ compass group higher us strategi creat customer-
centric salesforce-driven model improv retent acceler new busi win separ prolong
coronaviru outbreak would hit revenu compani flexibl cost model help protect short-term margin maintain
outperform price target
sustain growth resourc optim
execut rais pt
continu build foundat achiev target model take longer term view
busi given sturdier balanc sheet visibl growth given materi handl demand expand last middl
mile deliveri vehicl project underway potenti leverag hydrogen infrastructur believ begin enjoy
increasingli attract cost capit lender better understand financi strength growth prospect believ
transit next-gen stack technolog coupl scale benefit continu help drive margin expans
believ continu drive hydrogen fuel cost lower help margin note potent fuel cost
reduct compound stack effici improv
quick read monster perform februari
look favor upon cost report expect includ meaning acceler februari comp
trend month februari total comp increas vs street figur strength region
around world us comp rose two-year stack monthli trend improv januari
manag cite pt benefit februari comp relat coronaviru commentari suggest continu momentum
march view attract shorter-term beneficiari money flow long-term winner
help drive continu out-performance pleas see detail updat note titl recent under-perform
creat attract entri point upgrad outperform latest think
sale y/i cc in-lin our/street estim slightli
miss primarili asia-pac capac constraint de-stock follow japan vat increas om
versu higher opex ep versu our/street lower sales/high sg pull-
forward paragard ad partial off-set lower tax rate sale guidanc cc maintain ep guidanc
rang increas lower interest expens fed rate cut tax rate reiter
misight target us coronaviru expect impact sale sale guid
maintain expect offsetsmyday capac expans coupl new contract within fertil busi
lukewarm start tax season guidanc maintain
achiev tax season-start hope adjust ebitda/ep lower expect
season-to-d y/i tax file metric also lower anticip y/i date vs date basi appear take
share assist categori clarifi call lag industri february-end day vs day basi y/i also
assist net averag charg nac price net y/i do-it-yourself do-it-yourself categori lag industri
volum growth/incur declin do-it-yourself nac y/i howev maintain revenue/adjust ebitda
margin guidanc rang believ make earli tax season shortfal back half primarili attribut
pull-forward market spend adjust ebitda/ep perform
color fundament focu call
rockstar main act expect reiter outperform
thursday report earn highlight recent progress next month expect
deliv six-month primari efficaci analysi pivot rockstar trial chronic graft vs host diseas
cgvhd recal trial alreadi hit primari endpoint two month follow-up achiev respons rate
two patient cohortsand would surpris increment increas orr six month manag plan
hold pre-nda meet fda later month final regulatori requir timelin adequ cash
hand sustain oper potenti nda file continu view compel invest opportun
reiter outperform pt
updat ampl bridg clinic data gap
thursday syro report earn provid busi updat updat on-going studi
solid tumor r/r aml expect could significantli de-risk syro clinical-stag pipelin specif
expect see initi phase safeti pk/pd data year-end follow clinic activ result
separ result on-going phase studi also expect could establish proof-of-concept
azacitidin azac combin therapi relapsed/refractori aml set manag current focus heme/
onc develop effort given adequ cash sustain oper believ syro well posit achiev
key develop mileston catalyst distribut heavili skew toward late reiter outperform pt
report look pipelin newsflow sci-b-vac head toward us/eu review approv
net loss vs estimate appear best-in-class hepat vaccin sci-b-vac indic
phase perform vs standard-of-car engerix-b make way us/eu regulatori review later year
highlight sever upcom newsflow event stock-mov potenti evolv clinic data
glioblastoma follow compel initi observ top-lin result clinic evalu immuno-
therapeut chronic hepb infect believ asset offer monet potenti
partner opportun see like respect develop program continu meet success
believ investor current attribut littl valu either would buyer ahead upcom event
review build commerci voclosporin
follow impress year execut deliveri posit clinic result aurinia report financi result
host confer call discuss corpor progress aurinia continu lay foundat commercial-
stage therapeut compani key hire pre-commerci activ ahead plan nda submiss
voclosporin ln potenti commerci continu view voclosporin potenti first-in-class
importantli best-in-class agent ln particularli gsk phase studi readout benlysta ln proverbi
last shoe drop competit landscap follow result updat model stay bullish
review slowli build
cellecti cll report financi busi updat provid investor updat compani
indic clinic project continu recruit patient first cohort
phase clinic trial respect cohort respect trial take
month per cellecti averag believ could get close move
cohort next week view move cohort
compani confid manufactur process robust stabl replic see heighten
possibl materi clinic updat year-end updat model stay bullish
past year saw signific cgm market expans abbott libr see meaning increas
instal base driver includ continu strong market penetr grow intern presenc
expand access pharmaci intens patient last opportun recent reach high-
volum endocrinologist understand usag pattern cgm type patient outlook overal respond see
solid opportun ahead cost/coverag hurdl cite recent decis unitedhealthcar
cover intens data show cost save benefit even insulin trend
move right way toward next leg cgm market growth
report solid finish exceed consensu estim around revenu margin ep bill
revenu guidanc revis higher y/i midpt highlight includ strong
fortun enterpris product adopt yield new custom acv driven cloud migrat
hybrid zero trust achiev posit oper despit on-going intern invest
yoy dynamicscal access gateway pivot support land expand strategi believ remain
earli inning sizabl grow opportun driven larg enterpris migrat workload cloud
publish cloud util whitepap week encapsul invest recommend
importantli make money next approach focu compani uniqu
infrastructur high oper leverag cloud growth turn shift compute/network
shift histor creat major invest opportun use cloud provid saa content near zero
margin cost price correctli virtual sell see fsli vz potenti dish/fang
partnership well posit shift googl leverag underutil cloud infrastructur busi hour
success saa compani sell full suit enterpris commun servic cloud fsli
enabl true edg comput first time vz build new intellig network leverag massiv fiber
spectrum datacent
ethernet switch market declin yoy cloud spend slow grow macro uncertainti
caus enterpris push spend among tradit vendor junip outperform yoy cisco
yoy arista yoy yoy lag junip saw steadi dc demand amazon/enterpris earli
campu trend look favor cisco post weak result broad-bas macro weak neg impact dc/campu
demand arista neg impact facebook absenc although earli campu sign look posit saw longer
sale cycl campu minim dc contribut white-box revenu growth slow yoy chines
vendor revenu remain resili yoy trade tension eas expect materi impact
pressur demand suppli global greatest nt effect china thu lower switch market
growth forecast yoy impli revenu
reduc group estim coronaviru drag
reduc near-term estim group semiconductor compani continu wrestl depth/dur
coronaviru drag supply/demand situat remain fluid though consensu roughli near-term impact
emerg compani pre-announc shortfal and/or bake corona drag outlook report februari
chose includ corona outlook nxpi updat guidanc trim
estim coverag yet avgo/crus/intc/mpwr/mxim/qcom/txn point still
consid demand push vs cancel order cancel within normal rang like everyon continu
monitor situat close still expect sale reacceler remain bullish top structur growth
stori lead recoveri
presid kurt siever nomin ceo
nxpi announc unanim nomin kurt siever year presid ceo board
director ratifi sharehold meet may mr siever succeed outgo ceo clemmer
year ceo nxp ten year clemmer expect remain strateg advisor nxpi incom
ceo siever long time veteran compani join nxpi hold varieti leadership role sale
market product definit develop strategi gener manag across broad number market segment
play strateg role implement nxp high-perform mix signal strategi merger
freescal siever presid nxpi sinc believ groom ceo role believ siever
strong choic ceo given critic role evolut compani last five year dont expect
major shift strategi direct
finland nokia announc partnership reuter
helium announc new nationwid lorawan network
may biotech summit featur chemistri life process institut chicago il
juli montauk summit emerg life scienc montauk ny
